Sanofi India Ltd specializes in Pharmaceuticals within the Healthcare sector.
Sanofi India Ltd, with Security Code 500674, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | 7324 | 1366 | 7389 | 59.31 | 1127 | 65 | 100 | 1884 |
| 2024-01-01 | 2024-03-31 | 7,324.00 | 1,366.00 | 7,389.00 | 59.31 | -1,127.00 | 65.00 | -100.00 | 1,884.00 |
| 2023-10-01 | 2023-12-31 | 6,939.00 | 1,377.00 | 7,059.00 | 59.79 | -1,343.00 | 120.00 | -102.00 | 1,888.00 |
| 2023-10-01 | 2023-12-31 | 6,939.00 | 1,377.00 | 7,059.00 | 59.79 | -1,343.00 | 120.00 | -102.00 | 1,888.00 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | 1% |
| 3 Years: | -1% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 9% |
| 3 Years: | 5% |
| TTM: | 3% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 13% |
| 3 Years: | 12% |
| 1 Year: | 54% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 0% |
| TTM: | 0% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 13% |
| 3 Years: | 12% |
| 1 Year: | 54% |
French drug major Sanofi's India arm on Friday reported a 30.37 per cent decline in its net profit at Rs 184.96 crore for the quarter ended September 30, 2022.
Sanofi India said on Friday its arm Sanofi-Aventis has received the US health regulator's approval to market its diabetes drug here.
Sanofi India on Thursday announced the launch of a generic version of its diabetes drug Lantus (insulin glargine injection) in India.
Drug major Sanofi India on Wednesday reported a 17.6 per cent rise in its net profit to Rs 315.5 crore for the quarter ended September 30, 2022, on the back of higher sales.
